Forte Biosciences (FBRX) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Forte Biosciences (FBRX) Net Income towards Common Stockholders Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 18.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 92.37% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Forte Biosciences | 1.37 Bn | 1.31 Bn | - | -41.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.39% |
| Dec 31, 2025 | -231.19% |
| Sep 30, 2025 | -313.47% |
| Jun 30, 2025 | -91.56% |
| Mar 31, 2025 | -99.90% |
| Dec 31, 2024 | -15.93% |
| Sep 30, 2024 | 15.30% |
| Jun 30, 2024 | -40.85% |
| Mar 31, 2024 | -13.10% |
| Dec 31, 2023 | -28.12% |
| Sep 30, 2023 | -190.29% |
| Jun 30, 2023 | -181.69% |
| Mar 31, 2023 | -145.74% |
| Dec 31, 2022 | 61.16% |
| Sep 30, 2022 | 59.69% |
| Jun 30, 2022 | 88.80% |
| Mar 31, 2022 | 90.32% |
| Dec 31, 2021 | -25.44% |
| Sep 30, 2021 | 80.75% |
| Jun 30, 2021 | 31.29% |